| CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory L Mortara, P Castellani, R Meazza, G Tosi, A De Lerma Barbaro, ... Clinical cancer research 12 (11), 3435-3443, 2006 | 811 | 2006 |
| Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectin L Borsi, E Balza, M Bestagno, P Castellani, B Carnemolla, A Biro, ... International journal of cancer 102 (1), 75-85, 2002 | 427 | 2002 |
| Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer M Santimaria, G Moscatelli, GL Viale, L Giovannoni, G Neri, F Viti, ... Clinical Cancer Research 9 (2), 571-579, 2003 | 397 | 2003 |
| The fibronectin isoform containing the ED‐B oncofetal domain: a marker of angiogenesis P Castellani, G Viale, A Dorcaratto, G Nicolo, J Kaczmarek, G Querze, ... International journal of cancer 59 (5), 612-618, 1994 | 397 | 1994 |
| Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix B Carnemolla, L Borsi, E Balza, P Castellani, R Meazza, A Berndt, ... Blood, The Journal of the American Society of Hematology 99 (5), 1659-1665, 2002 | 364 | 2002 |
| Selective targeted delivery of TNFα to tumor blood vessels L Borsi, E Balza, B Carnemolla, F Sassi, P Castellani, A Berndt, ... Blood 102 (13), 4384-4392, 2003 | 313 | 2003 |
| A high-affinity human antibody that targets tumoral blood vessels L Tarli, E Balza, F Viti, L Borsi, P Castellani, D Berndorff, L Dinkelborg, ... Blood, The Journal of the American Society of Hematology 94 (1), 192-198, 1999 | 269 | 1999 |
| Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells. L Borsi, B Carnemolla, P Castellani, C Rosellini, D Vecchio, G Allemanni, ... The Journal of cell biology 104 (3), 595-600, 1987 | 243 | 1987 |
| Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues J Kaczmarek, P Castellani, G Nicolo, B Spina, G Allemanni, L Zardi International journal of cancer 59 (1), 11-16, 1994 | 205 | 1994 |
| Phage antibodies with pan‐species recognition of the oncofoetal angiogenesis marker fibronectin ED‐B domain B Carnemolla, D Neri, P Castellani, A Leprini, G Neri, A Pini, G Winter, ... International journal of cancer 68 (3), 397-405, 1996 | 201 | 1996 |
| Differentiation between high-and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin P Castellani, L Borsi, B Carnemolla, A Biro, A Dorcaratto, GL Viale, D Neri, ... The American journal of pathology 161 (5), 1695-1700, 2002 | 177 | 2002 |
| Transforming growth factor-β regulates the splicing pattern of fibronectin messenger RNA precursor L Borsi, P Castellani, AM Risso, A Leprini, L Zardi FEBS letters 261 (1), 175-178, 1990 | 177 | 1990 |
| Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody B Carnemolla, P Castellani, M Ponassi, L Borsi, S Urbini, G Nicolo, ... The American journal of pathology 154 (5), 1345-1352, 1999 | 172 | 1999 |
| Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues PG Natali, MR Nicotra, A Bigotti, C Botti, P Castellani, AM Risso, L Zardi International journal of cancer 47 (6), 811-816, 1991 | 169 | 1991 |
| Transformed human cells release different fibronectin variants than do normal cells. P Castellani, A Siri, C Rosellini, E Infusini, L Borsi, L Zardi The Journal of cell biology 103 (5), 1671-1677, 1986 | 155 | 1986 |
| Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin CM Matter, PK Schuler, P Alessi, P Meier, R Ricci, D Zhang, C Halin, ... Circulation research 95 (12), 1225-1233, 2004 | 139 | 2004 |
| DAMPs and inflammatory processes: the role of redox in the different outcomes S Carta, P Castellani, L Delfino, S Tassi, R Vene, A Rubartelli Journal of leukocyte biology 86 (3), 549-555, 2009 | 138 | 2009 |
| Redox remodeling allows and controls B-cell activation and differentiation R Vené, L Delfino, P Castellani, E Balza, M Bertolotti, R Sitia, A Rubartelli Antioxidants & redox signaling 13 (8), 1145-1155, 2010 | 112 | 2010 |
| The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants J Ceccarelli, L Delfino, E Zappia, P Castellani, M Borghi, S Ferrini, ... International Journal of Cancer 123 (8), 1770-1778, 2008 | 104 | 2008 |
| Targeted Delivery of Tumor Necrosis Factor-α to Tumor Vessels Induces a Therapeutic T Cell–Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different … E Balza, L Mortara, F Sassi, S Monteghirfo, B Carnemolla, P Castellani, ... Clinical cancer research 12 (8), 2575-2582, 2006 | 103 | 2006 |
